{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:06:17Z","timestamp":1790679977803,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministry of Economy and Competitiveness","doi-asserted-by":"publisher","award":["PI17\/00690"],"award-info":[{"award-number":["PI17\/00690"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD21\/0016\/0001"],"award-info":[{"award-number":["RD21\/0016\/0001"]}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD24\/0005\/0001"],"award-info":[{"award-number":["RD24\/0005\/0001"]}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD21\/0016\/0010"],"award-info":[{"award-number":["RD21\/0016\/0010"]}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD24\/0005\/0018"],"award-info":[{"award-number":["RD24\/0005\/0018"]}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD21\/0016\/0027"],"award-info":[{"award-number":["RD21\/0016\/0027"]}]},{"name":"Health Outcomes-Oriented Cooperative Research Networks","award":["RD24\/0005\/0015"],"award-info":[{"award-number":["RD24\/0005\/0015"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Current guidelines suggest a unique 10 year cardiovascular disease (CVD) risk threshold for the oldest to consider lipid-lowering treatment for CVD prevention. We aimed to assess the benefit of initiating primary prevention with statins in non-diabetic adults aged 70\u201389 according to their SCORE2-OP, and to explore risk thresholds for different ages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted an observational retrospective cohort study with the Catalan primary care database (SIDIAP) with an intention-to-treat approach. We assessed incident CVD (myocardial infarction and stroke), all-cause mortality, and adverse effects. Overall and age-stratified propensity-adjusted Cox proportional hazard models were fitted, using restricted cubic splines for the treatment interaction with SCORE2-OP. We analysed 167 360 individuals (mean age 77.70 years; 36.9% men). The mean baseline SCORE2-OP risk was 13.81%. Overall, treatment was not associated with a CVD reduction in lower risks, with a protective association becoming stable around a SCORE2-OP of 16% [hazard ratio (HR) = 0.90 (0.84\u20130.96)]. The different age groups reached similar protective associations (HR \u2248 0.85), but at different estimated risks. A mild significant increase of type 2 diabetes was observed in statin initiators [1.07 (1.02\u20131.12)]. We did not observe a protective association with all-cause mortality across the whole estimated risk spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Age-specific risk thresholds of the SCORE2-OP estimated risk may be further developed and considered when weighing the benefits of initiating primary prevention of incident CVD with statins in non-diabetic adults aged 70 and older. Our results do not support treatment initiation of primary prevention to reduce all-cause mortality at any level of estimated CVD risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag469","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:32:15Z","timestamp":1788521535000},"source":"Crossref","is-referenced-by-count":0,"title":["SCORE2-OP-guided statin initiation for primary prevention in adults aged 70\u201389 years without diabetes: evidence for age-specific risk thresholds"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-0819","authenticated-orcid":false,"given":"Llu\u00eds","family":"Zacar\u00edas-Pons","sequence":"first","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-3292","authenticated-orcid":false,"given":"Jordi","family":"Blanch","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-952X","authenticated-orcid":false,"given":"Lia","family":"Alves-Cabratosa","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7877-2233","authenticated-orcid":false,"given":"Gina","family":"Dom\u00ednguez-Armengol","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-9521","authenticated-orcid":false,"given":"Ruth","family":"Mart\u00ed-Lluch","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]},{"name":"Institut D'Investigaci\u00f3 Biom\u00e8dica de Girona (IdIBGi), Dr. Josep Trueta University Hospital , C\/Dr. Castany s\/n, Salt, Girona 17190 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-4775","authenticated-orcid":false,"given":"Francesc","family":"Ribas-Aulinas","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-6387","authenticated-orcid":false,"given":"Anna","family":"Ponjoan","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]},{"name":"Institut D'Investigaci\u00f3 Biom\u00e8dica de Girona (IdIBGi), Dr. Josep Trueta University Hospital , C\/Dr. Castany s\/n, Salt, Girona 17190 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Romero","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-8302","authenticated-orcid":false,"given":"Luis","family":"Garc\u00eda-Ortiz","sequence":"additional","affiliation":[{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]},{"name":"Unidad de Investigaci\u00f3n de Atenci\u00f3n Primaria de Salamanca (APISAL), Gerencia de Atenci\u00f3n Primaria de Salamanca, Gerencia Regional de Salud de Castilla y Le\u00f3n (SACYL), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL) , Av. Portugal, 83-2\u00b0, Salamanca 37005 ,","place":["Spain"]},{"name":"Departamento de Ciencias Biom\u00e9dicas y del Diagn\u00f3stico, Universidad de Salamanca , Calle Alfonso X el Sabio, Salamanca 37007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3931-5304","authenticated-orcid":false,"given":"Isabel","family":"del Cura-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]},{"name":"Primary Care Research Unit, Gerencia de Atenci\u00f3n Primaria, SERMAS , Madrid ,","place":["Spain"]},{"name":"Departamento de Medicina Preventiva y Salud P\u00fablica, Rey Juan Carlos University , Alcorc\u00f3n, Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid ,","place":["Spain"]},{"name":"Aging Research Center, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-5537","authenticated-orcid":false,"given":"Rafel","family":"Ramos","sequence":"additional","affiliation":[{"name":"Grup D'Investigaci\u00f3 en Salut Vascular de Girona (ISV-Girona), Institut Universitari D'Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol i Gurina -IDIAPJGol , C\/Santa Clara, 35, 2nd floor, Girona, Catalonia 17001 ,","place":["Spain"]},{"name":"Chronicity, Primary Care, and Health Promotion Networks (RICAPPS), ISCIII , Girona, Madrid and Castilla y Le\u00f3n ,","place":["Spain"]},{"name":"Institut D'Investigaci\u00f3 Biom\u00e8dica de Girona (IdIBGi), Dr. Josep Trueta University Hospital , C\/Dr. Castany s\/n, Salt, Girona 17190 ,","place":["Spain"]},{"name":"Department of Medical Sciences, Universitat de Girona, Edifici Centre , C\/Emili Grahit, 77, esc. B, 2n, Campus Centre, Girona, Catalonia 17003 ,","place":["Spain"]},{"name":"Institut Catal\u00e0 de Salut (ICS) Serveis d'Atenci\u00f3 Prim\u00e0ria, , Girona area, Catalunya ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026092906515092900_zwag469-B1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjqcco\/qcad033","article-title":"Burden of cardiovascular disease among elderly: based on the global burden of disease study 2019","volume":"10","author":"Qu","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026092906515092900_zwag469-B3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B4","author":"United Nations Population Division"},{"key":"2026092906515092900_zwag469-B5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jgs.16227","article-title":"Statins after myocardial infarction in the oldest: a cohort study in the clinical practice research datalink database","volume":"68","author":"Lefeber","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"2026092906515092900_zwag469-B6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40266-015-0290-9","article-title":"Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis","volume":"32","author":"Teng","year":"2015","journal-title":"Drugs Aging"},{"key":"2026092906515092900_zwag469-B9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.7326\/M24-0004","article-title":"Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study: real-world evidence from a target trial emulation study","volume":"177","author":"Xu","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026092906515092900_zwag469-B10","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"2026092906515092900_zwag469-B11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B12","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026092906515092900_zwag469-B13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/eurjpc\/zwae383","article-title":"Systematic coronary risk evaluation 2 for older persons: 10 years risk validation, clinical utility, and potential improvement","volume":"32","author":"Belahnech","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026092906515092900_zwag469-B14","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026092906515092900_zwag469-B15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026092906515092900_zwag469-B16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2015.02.025","article-title":"Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all","volume":"65","author":"Navar-Boggan","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026092906515092900_zwag469-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-1279","article-title":"Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: a modeling study","volume":"170","author":"Yebyo","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026092906515092900_zwag469-B18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12872-020-01697-6","article-title":"Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study","volume":"20","author":"Yebyo","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2026092906515092900_zwag469-B19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12872-024-04242-x","article-title":"Optimal risk thresholds for prescribing statins as primary prevention of cardiovascular disease in Iranian general population: a benefit-harm modelling study","volume":"24","author":"Khalili","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2026092906515092900_zwag469-B20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000633","article-title":"Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study","volume":"3","author":"Xu","year":"2024","journal-title":"BMJ Med"},{"key":"2026092906515092900_zwag469-B21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.medcli.2012.01.020","article-title":"[SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]","volume":"138","author":"Bol\u00edbar","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"2026092906515092900_zwag469-B22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CLEP.S206770","article-title":"How well can electronic health records from primary care identify Alzheimer\u2019s disease cases?","volume":"11","author":"Ponjoan","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026092906515092900_zwag469-B23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/CLEP.S225568","article-title":"Validation of cancer diagnoses in electronic health records: results from the information system for research in primary care (SIDIAP) in northeast Spain","volume":"11","author":"Recalde","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026092906515092900_zwag469-B24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.recesp.2011.07.017","article-title":"Validity for use in research on vascular diseases of the SIDIAP (information system for the development of research in primary care): the EMMA study","volume":"65","author":"Ramos","year":"2012","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026092906515092900_zwag469-B25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2026092906515092900_zwag469-B26","first-page":"179","article-title":"[Constructing a deprivation index based on census data in large Spanish cities(the MEDEA project)]","volume":"22","author":"Dom\u00ednguez-Berj\u00f3n","year":"2008","journal-title":"Gac Sanit"},{"key":"2026092906515092900_zwag469-B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2026092906515092900_zwag469-B28","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"2026092906515092900_zwag469-B29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026092906515092900_zwag469-B30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/pds.1673","article-title":"Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score","volume":"17","author":"Austin","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092906515092900_zwag469-B31","unstructured":"R Core Team\n          . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"key":"2026092906515092900_zwag469-B32","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2026092906515092900_zwag469-B33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092906515092900_zwag469-B34","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ije\/dyad011","article-title":"Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20-79 years","volume":"52","author":"M\u00f8rland","year":"2023","journal-title":"Int J Epidemiol"},{"key":"2026092906515092900_zwag469-B35","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/heartjnl-2022-322278","article-title":"Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis","volume":"109","author":"Dagenais","year":"2023","journal-title":"Heart"},{"key":"2026092906515092900_zwag469-B36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation"},{"key":"2026092906515092900_zwag469-B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2020.05.016","article-title":"Association of statin use with disability-free survival and cardiovascular disease among healthy older adults","volume":"76","author":"Zhou","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026092906515092900_zwag469-B38","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026092906515092900_zwag469-B39","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092906515092900_zwag469-B40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12916-021-02009-1","article-title":"Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies","volume":"19","author":"Awad","year":"2021","journal-title":"BMC Med"},{"key":"2026092906515092900_zwag469-B41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2020.7848","article-title":"Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older","volume":"324","author":"Orkaby","year":"2020","journal-title":"JAMA"},{"key":"2026092906515092900_zwag469-B42","article-title":"Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records","volume":"9","author":"Gitsels","year":"2021","journal-title":"Fam Med Community Health"},{"key":"2026092906515092900_zwag469-B43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2026092906515092900_zwag469-B44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","article-title":"Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials: results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"2026092906515092900_zwag469-B45","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.2337\/dc13-0490","article-title":"Relationship of sex to diabetes risk in statin trials","volume":"36","author":"Goodarzi","year":"2013","journal-title":"Diabetes Care"},{"key":"2026092906515092900_zwag469-B46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41256-023-00311-4","article-title":"Prevalence and trends of polypharmacy in U.S. adults, 1999-2018","volume":"8","author":"Wang","year":"2023","journal-title":"Glob Health Res Policy"},{"key":"2026092906515092900_zwag469-B47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag469\/70965429\/zwag469.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag469\/70965429\/zwag469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:52:12Z","timestamp":1790679132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag469\/8786021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag469","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"zwag469"}}